Yunovia

Yunovia is a South Korean biotechnology company established in 2023 as a spin-off from Ildong Pharmaceutical's research and development division. The company is dedicated to developing a diverse pipeline of innovative therapies, with a primary focus on metabolic diseases, gastrointestinal disorders, and central nervous system conditions. Its lead clinical assets include a potassium-competitive acid blocker (P-CAB) for gastric acid-related diseases and an oral small molecule GLP-1 receptor agonist for obesity and type 2 diabetes. Yunovia also maintains active programs in non-alcoholic steatohepatitis (NASH) and Parkinson's disease. By operating as an independent entity, the company seeks to enhance R&D efficiency and facilitate global licensing deals and investment.